Envista Holdings Co. (NYSE:NVST) General Counsel Mark E. Nance sold 4,321 shares of the stock in a transaction that occurred on Tuesday, September 14th. The stock was sold at an average price of $44.01, for a total value of $190,167.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Mark E. Nance also recently made the following trade(s):
- On Tuesday, August 3rd, Mark E. Nance sold 304 shares of Envista stock. The stock was sold at an average price of $44.10, for a total value of $13,406.40.
Shares of NYSE NVST traded down $0.23 during trading hours on Thursday, hitting $43.45. The company’s stock had a trading volume of 1,579,861 shares, compared to its average volume of 1,863,974. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.85 and a current ratio of 1.12. The stock has a market cap of $7.01 billion, a price-to-earnings ratio of 24.41, a P/E/G ratio of 0.80 and a beta of 1.92. Envista Holdings Co. has a 12 month low of $22.51 and a 12 month high of $46.52. The business has a 50-day simple moving average of $42.03 and a 200-day simple moving average of $42.37.
A number of institutional investors have recently bought and sold shares of NVST. Eagle Bay Advisors LLC bought a new stake in Envista during the 2nd quarter valued at approximately $39,000. Altshuler Shaham Ltd purchased a new position in shares of Envista during the first quarter valued at approximately $41,000. AllSquare Wealth Management LLC purchased a new position in shares of Envista during the first quarter valued at approximately $55,000. Harvest Fund Management Co. Ltd raised its holdings in Envista by 63.9% in the 1st quarter. Harvest Fund Management Co. Ltd now owns 1,796 shares of the company’s stock worth $73,000 after acquiring an additional 700 shares during the last quarter. Finally, C M Bidwell & Associates Ltd. grew its position in Envista by 2,886.7% in the 1st quarter. C M Bidwell & Associates Ltd. now owns 2,240 shares of the company’s stock worth $91,000 after purchasing an additional 2,165 shares during the period.
Separately, Piper Sandler upped their target price on Envista from $45.00 to $47.00 and gave the company a “neutral” rating in a report on Wednesday, August 4th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $43.67.
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.
See Also: Debt-To-Equity Ratio
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.